Proteomics International (ASX:PIQ) - Managing Director, Richard Lipscombe
Managing Director, Richard Lipscombe
Source: Proteomics International
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Proteomics International (PIQ) has received $200,000 in COVID-19-related research grants from the Western Australian government
  • The money has been granted in two endowments for the diagnosis and triage of COVID-19 patients
  • With faster, more efficient diagnostic and treatment tools, it is believed Australia will be able to open up its state and international borders sooner, helping the country’s post-pandemic recovery
  • If either or both tests are successful and approved for market, Proteomics could save a number of lives, make communities safer, and possibly make a fair bit of money along the way
  • Proteomics International is down three per cent today to a price of 32 cents per share

Predictive diagnostics researcher Proteomics International (PIQ) has received $200,000 in COVID-19-related research grants from the Western Australian government.

The money has been granted across two endowments: firstly, in relation to PIQ’s research to develop a rapid diagnostic test for the identification of the virus; and secondly, to isolate biomarkers that may be indicators for the severity of the infection.

Both projects are to be completed in the next 12 months or less and are aimed at the improved diagnosis and treatment of COVID-19 patients.

With faster, more efficient diagnostic and treatment tools, it is believed Australia will be able to open up its state and international borders sooner, helping the country’s post-pandemic recovery.

The tests

While both tests are aimed at faster diagnosis of COVID-19, each takes a different approach, with different outcomes in mind.

The rapid diagnostic test is aimed at producing a reliable result without invasive sinus swab tests. Saliva will be used instead, providing the potential for faster results and far less patient discomfort.

Universal, rapid, non-invasive testing could enable asymptomatic carriers to be quickly diagnosed and isolated, enabling authorities to safely reopen sooner while the pandemic is still potentially active within a populace.

The protein biomarker test will be aimed at testing, which may reveal the potential severity of the patient’s case.

While most people are either asymptomatic or suffer only mild symptoms of the virus, 14 per cent of infections are severe and require oxygen, while six per cent are life-threatening and require ventilation.

PIQ will aim to develop a test which picks up the biomarkers associated with the severity of the infection, which will enable the rapid triage of those testing positive, potentially before severe symptoms develop.

If either or both tests are successful and approved for market, Proteomics could save a number of lives, make communities safer, and possibly make a fair bit of money along the way.

Proteomics International is down three per cent today to a price of 32 cents per share as at 3:05 pm AEST.

piq by the numbers
More From The Market Online

Emvision Medical Devices unlocks traumatic brain injury First Responder with $3m grant

EMVision Medical Devices has been awarded a $3 million grant the Australian government’s national CRC-P program.

Immutep obtains encouraging disease-free survival in phase II sarcoma trial

Immutep has unveiled new data from the investigator-initiated EFTISARC-NEO Phase II study evaluating radiotherapy before surgery.

Xenitra signs JD Health strategic Chinese agreement targeting $100m in sales

Xenitra subsidiary Shengdi Pharmaceutical has entered into a three-year strategic agreement with China’s largest online healthcare…

Racura Oncology receives positive results in study of RC110 and RC220

Racura Oncology has obtained positive results from a study into RC220, the company’s proprietary formulation of…